Why LYEL rose 48.1% on Nov 4 2026: strong clinical data
LYEL+48.1%on Wed Nov 4 2026
Lyell Immunopharma, Inc. Common Stock was up 48.1% on the day at $15.95, ranked #10 on 58.5× its usual five-minute volume, when TapeRank recorded this spike at 10:26 ET during regular hours.
THE DAY ON THE LIST · 1 EVENT
- 10:26 ETMOVER · REGULAR
$15.95 · ▲ 48.1% ON THE DAY · 58.5× 5M RVOL · RANK #10
JUSTIFIEDCONFIDENCE5/5LYEL is up 46.5% on strong interim clinical data showing 91% overall and 77% complete response rates in a pivotal CAR-T trial, with additional ASH data scheduled. The clinical readout is a concrete, material catalyst that can support a sharp repricing, while the concurrent $80 million private placement creates near-term resale dilution risk.
WHYA 46.5% move is large, but it is supported by unusually strong clinical response data; the 7.4 million newly issued shares add dilution risk rather than negate the catalyst.ANALYZED 10:25 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 10:26 ET
LAST15.95DAY▲ 48.1%5 MIN▲ 3.37%5M RVOL58.5×5M $VOL$632KFLOAT*24.5MRANK#10SESSIONREGULARVWAP14.58HOD15.95LOD11.23OR HIGH14.26OR LOW12.09PREV CLOSE10.77PM HIGH12.05PM LOW11.23GAP▲ 12.26%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $12.09, +12.3% on the previous close of $10.77
- 09:30 ETRegular-session low, $12.09
- 11:22 ETRegular-session high, $16.73
- 15:59 ETLast trade of the regular session, $15.43, +43.3% on the previous close of $10.77
- Volume: 1.1M shares in regular hours, 7K before the open
LYEL opened at $12.09, its session low, after the previous close of $10.77, then climbed to an $16.73 high by 11:22 ET before ending the regular session at $15.43. TapeRank read the move as justified by strong interim clinical data for rondecabtagene autoleucel, including a 91% overall response rate and 77% complete response rate, with additional ASH data scheduled; the concurrent $80 million private placement of 7.4 million shares added near-term resale dilution risk. There were no halts, and regular-hours volume reached 1.1 million shares.
WRITTEN WED NOV 4 2026 16:01 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 09:11 ETLyell Immunopharma Announces ~$80M Private Placement Of 7.4M Shares At $10.77/ShareBenzinga
- 09:09 ETLyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response RateBenzinga
- 09:05 ET8-K — Unregistered Sales of Equity SecuritiesSEC 8-K
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list